Merck KGaA: sees profitable growth in coming years
(CercleFinance.com) - German science and technology group Merck expects to post sustainable profitable growth at all its three businesses in the coming years, the company said at its capital markets day on Wednesday.
For 2019, Merck continues to assume that it will increase key sales, EBITDA and EPS, while also aiming at profitable growth for 2020 and beyond, it said to analysts and investors.
In healthcare, Merck said it plans to achieve additional annual sales of around 2 billion euros with new medicines by 2022.
In the coming years, its life science business is expected to continue to outperform growth in the market, delivering growth of 5% to 8% per year, it said.
Finally, the performance materials unit is expected to return to growth as from 2020, posting growth of 2%-to-3% from 2020.
The Merck share is currently up 1.8% at 94.8 euros in Frankfurt.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
For 2019, Merck continues to assume that it will increase key sales, EBITDA and EPS, while also aiming at profitable growth for 2020 and beyond, it said to analysts and investors.
In healthcare, Merck said it plans to achieve additional annual sales of around 2 billion euros with new medicines by 2022.
In the coming years, its life science business is expected to continue to outperform growth in the market, delivering growth of 5% to 8% per year, it said.
Finally, the performance materials unit is expected to return to growth as from 2020, posting growth of 2%-to-3% from 2020.
The Merck share is currently up 1.8% at 94.8 euros in Frankfurt.
Copyright (c) 2019 CercleFinance.com. All rights reserved.